2016•Clinical Cancer ResearchOpen access

Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib

Pavan Bachireddy, Catherine J. Wu

Abstract

The clinical success of agents targeting the B-cell receptor signaling pathway in chronic lymphocytic leukemia (CLL) may also derive from disrupting the CLL microenvironment. Investigation of the immunomodulatory effects of these agents illuminates the unique immunobiology of CLL and highlights potential targets for dismantling the chronic inflammatory drive. See related article by Niemann et al., p. 1572.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 10 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Ibrutinib, Chronic lymphocytic leukemia, Leukemia, Cancer, Medicine, Cancer research, Immunology, Internal medicine